Twitter Honors Girl with Terminal Non-Hodgkin’s Lymphoma

Alice Pyne, a 15-year-old British girl dealing with terminal non-Hodgkin’s lymphoma, didn’t realize the power of Twitter prior to becoming something of a new age icon.

Upon learning that she was suffering from the deadly disease, Pyne opted to create a bucket list. Among things that she listed was the seemingly lofty hope that she would become a trending topic on Twitter.

"I've been fighting cancer for almost four years and now I know that the cancer is gaining in on me, and it doesn't look like I'm going to win this one," she said on her blog. "I'm hoping to write in here as much as I can and I'm also going to show my bucket list, which I'm trying to get done before I have to go."

Other goals on the bucket list: to make everyone sign up to be a bone marrow donor, to swim with sharks, to have a purple Apple iPad (her mom will borrow one), to be a dolphin trainer, to go to Cadbury World and eat loads of chocolate and to be a trending topic on Twitter.

That last wish proved easier than she ever could have expected. A mere three days after her first blog entry on June 6, #alicebucketlist began to trend on twitter.

"I can't believe that so many people have taken an interest in my blog," Alice wrote today. "Now for mega exciting news... I'm off to see Take That this weekend, can you believe it?"

Pyne hopes that with her newfound fame she will be able to draw some much-needed attention to donating bone marrow.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap